Description:
The purpose of this study is to determine the efficacy of cusatuzumab in combination with
azacitidine in participants with previously untreated acute myeloid leukemia (AML) who are
not eligible for intensive chemotherapy.
Title
- Brief Title: A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy
- Official Title: A Phase 2 Study of Cusatuzumab Plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy
Clinical Trial IDs
- ORG STUDY ID:
CR108609
- SECONDARY ID:
2019-000473-23
- SECONDARY ID:
74494550AML2001
- NCT ID:
NCT04023526
Conditions
Interventions
Drug | Synonyms | Arms |
---|
Azacitidine | | Azacitidine 75 mg/m^2 and Cusatuzumab 10 mg/kg |
Cusatuzumab | JNJ-74494550 | Azacitidine 75 mg/m^2 and Cusatuzumab 10 mg/kg |
Purpose
The purpose of this study is to determine the efficacy of cusatuzumab in combination with
azacitidine in participants with previously untreated acute myeloid leukemia (AML) who are
not eligible for intensive chemotherapy.
Detailed Description
AML is a heterogeneous disease characterized by uncontrolled clonal expansion of
hematopoietic progenitor cells. As the most common form of acute leukemia, AML accounts for
the largest number of annual deaths from leukemia. Over 95 percent (%) of AML blasts
harvested from newly diagnosed AML participants expressed Cluster of Differentiation (CD) 70
on the cell surface. Cusatuzumab (JNJ-74494550) is a humanized monoclonal antibody of camelid
origin, binding with tight affinity to human CD70. Cusatuzumab has been modified to induce
enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) for therapeutic use in
participants with cancer. Azacitidine is a pyrimidine nucleoside analogue of cytidine with
antineoplastic activity and is indicated for the treatment of adult participants with AML or
intermediate 2 and high-risk myelodysplastic syndrome (MDS) with greater than 20% marrow
blasts who are not eligible for hematopoietic stem cell transplantation. This study will
evaluate 2 doses of cusatuzumab in combination with standard dose azacitidine in participants
with AML who are not candidates for intensive chemotherapy (Part 1). Part 1 data will be
reviewed by a Data Review Committee to select a preferred dose of cusatuzumab. The study will
include a Screening Phase (28 days prior to randomization), a Treatment Phase, and a
Follow-up Phase. The study includes evaluations like vital signs, electrocardiogram,
spirometry test, serum chemistry and hematology tests. The study will be conducted for an
approximate duration of 2 years.
Trial Arms
Name | Type | Description | Interventions |
---|
Azacitidine 75 mg/m^2 and Cusatuzumab 10 mg/kg | Experimental | Participants will receive azacitidine 75 milligram per meter square (mg/m^2) subcutaneously (SC) or intravenously (IV) on Day 1 through Day 7 and cusatuzumab 10 milligram per kilogram (mg/kg) IV on Day 3 and Day 17 of each 28-day cycle in Part 1. Part 1 findings will be reviewed by a data review committee. | |
Azacitidine 75 mg/m^2 and Cusatuzumab 20 mg/kg | Experimental | Participants will receive azacitidine 75 mg/m^2 SC or IV on Day 1 through Day 7 and cusatuzumab 20 mg/kg IV on Day 3 and Day 17 of each 28-day cycle in Part 1. Part 1 findings will be reviewed by a data review committee. | |
Eligibility Criteria
Inclusion Criteria:
- Acute myeloid leukemia (AML) according to World Health Organisation (WHO) 2016
criteria and fulfilling all of the following criteria that defines those who are "not
candidates for intensive chemotherapy":
1. greater than or equal to (>=)75 years of age or
2. less than (<) 75 years of age with at least one of the following comorbidities:
Eastern Cooperative Oncology Group (ECOG) Performance Status of 2; Severe cardiac
comorbidity defined as congestive heart failure or ejection fraction less than or
equal to (<=) 50 percent (%); Severe pulmonary comorbidity defined as documented
pulmonary disease with lung diffusing capacity for carbon monoxide (DLCO) <=65%
of expected, or forced expiratory volume in 1 second (FEV1) <=65% of expected or
dyspnea at rest requiring oxygen; Moderate hepatic impairment defined according
to NCI organ dysfunction classification criteria (total bilirubin >=1.5 up to 3
times upper limit of normal [ULN]); Creatinine clearance <45 milliliter per
minute per 1.73 meter square (mL/ min/1.73 m^2); Comorbidity that, in the
Investigator's opinion, makes the participant unsuitable for intensive
chemotherapy and must be documented and approved by the Sponsor before
randomization
- De novo or secondary AML
- Previously untreated AML (except: emergency leukapheresis, hydroxyurea, and/or 1 dose
of cytarabine [example: 1-2 gram per meter square {g/m^2}] during the Screening Phase
to control hyperleukocytosis. These treatments must be discontinued >=24 hours prior
to start of study drug). Empiric all trans retinoic acid (ATRA) treatment for presumed
acute promyelocytic leukemia (APL) is permitted but APL must be ruled out and ATRA
must be discontinued >=24 hours prior to the start of study drug
- Not eligible for an allogeneic hematopoietic stem cell transplantation
- ECOG Performance Status score of 0, 1 or 2
Exclusion Criteria:
- Acute promyelocytic leukemia
- Leukemic involvement or clinical symptoms of leukemic involvement of the central
nervous system
- Use of immune suppressive agents for the past 4 weeks before the first administration
of cusatuzumab on Cycle 1 Day 3. For regular use of systemic corticosteroids,
participants may only be included if free of systemic corticosteroids for a minimum of
5 days before the first administration of cusatuzumab. Treatment of adrenal
insufficiency with physiologic replacement doses of corticosteroids are allowed
- Prior treatment with a hypomethylating agent for treatment of AML or myelodysplastic
syndrome (MDS)
- Active malignancies (that is, progressing or requiring treatment in the last 24
months) other than the disease being treated under the study
- Any active systemic infection
- Known allergies, hypersensitivity, or intolerance to cusatuzumab or azacitidine or its
excipients (that is, mannitol, an excipient of azacitidine)
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Percentage of Participants with Complete Response (CR) |
Time Frame: | Up to 1.5 years |
Safety Issue: | |
Description: | Percentage of participants with complete response based on European Leukemia Network (ELN) 2017 response criteria assessment will be reported. |
Secondary Outcome Measures
Measure: | Percentage of Participants with CR with Partial Hematological Recovery (CRh) |
Time Frame: | Up to 1.5 years |
Safety Issue: | |
Description: | Percentage of participants with CRh will be reported based on ELN 2017 response criteria assessment. |
Measure: | Percentage of Participants with CR plus CRh |
Time Frame: | Up to 1.5 years |
Safety Issue: | |
Description: | Percentage of participants with CR plus CRh will be reported based on ELN 2017 response criteria assessment. |
Measure: | Percentage of Participants with CR with Incomplete Recovery (CRi) |
Time Frame: | Up to 1.5 years |
Safety Issue: | |
Description: | Percentage of participants with CRi will be reported based on ELN 2017 response criteria assessment. |
Measure: | Overall Response Rate (ORR) |
Time Frame: | Up to 1.5 years |
Safety Issue: | |
Description: | ORR is defined as percentage of participants with CR, CRh and CRi based on ELN 2017 response criteria assessment. |
Measure: | Percentage of Participants with CR without MRD |
Time Frame: | Up to 1.5 years |
Safety Issue: | |
Description: | Percentage of participants with CR without minimal residual disease (MRD) will be reported and is defined as less than 1 blast or leukemic stem cell in 1,000 leukocytes (MRD level <10^-3; determined by central lab). |
Measure: | Percentage of Participants with Negative MRD who Achieved CR, CRh, CRi, or Morphologic Leukemia-free State (MLFS) |
Time Frame: | Up to 1.5 years |
Safety Issue: | |
Description: | Percentage of participants with negative MRD who achieved CR, CRh, CRi, or MLFS will be reported and is defined as less than (<) 1 blast or leukemic stem cell in 1,000 leukocytes (MRD level <10^-3). |
Measure: | Time to Response |
Time Frame: | Up to 1.5 years |
Safety Issue: | |
Description: | Time to response, defined as time from randomization in Part 1 to achieving the first response of CR, CRh, or CRi. |
Measure: | Duration of Response |
Time Frame: | Up to 1.4 years |
Safety Issue: | |
Description: | Duration of response is defined as time from achieving the first response of CR, CRh, or CRi to disease relapse or death from any cause. |
Measure: | Red Blood Cell (RBC) or Platelets Transfusion Independence |
Time Frame: | Up to 1.5 years |
Safety Issue: | |
Description: | Transfusion independence (RBC or platelets) is defined as a period of at least 56 consecutive days with no transfusion between first dose of study drug and the last dose of study drug +30 days. |
Measure: | Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) |
Time Frame: | Up to 1.9 years |
Safety Issue: | |
Description: | An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. An SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above. |
Measure: | Minimum Serum Concentration (Cmin) of Cusatuzumab |
Time Frame: | Up to 1.9 years |
Safety Issue: | |
Description: | Cmin is the minimum observed serum concentration. |
Measure: | Maximum Serum Concentration (Cmax) of Cusatuzumab |
Time Frame: | Up to 1.9 years |
Safety Issue: | |
Description: | Cmax is the maximum observed serum concentration. |
Measure: | Number of Participants with Anti-cusatuzumab Antibodies |
Time Frame: | Up to 1.9 years |
Safety Issue: | |
Description: | Number of participants exhibiting anti-drug antibodies for cusatuzumab alone and in combination with azacitidine will be reported. |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Active, not recruiting |
Lead Sponsor: | Janssen Research & Development, LLC |
Last Updated
August 13, 2021